Number of Research Targets, Gross, Oncology

No definition available.

Name:	carm_NumberOfResearchTargetsGrossOncology
Namespace Prefix:	carm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Research Targets Nominated, Oncology

+ References

No definition available.

+ Details

Name:	carm_NumberOfResearchTargetsNominatedOncology
Namespace Prefix:	carm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Research Targets Nominated, Replacements

+ References

No definition available.

+ Details

Name:	carm_NumberOfResearchTargetsNominatedReplacements
Namespace Prefix:	carm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Research Targets, Terminated, Autoimmune

+ References

No definition available.

+ Details

Name:	carm_NumberOfResearchTargetsTerminatedAutoimmune
Namespace Prefix:	carm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Research Targets, Terminated, Oncology

+ References

No definition available.

+ Details

Name:	carm_NumberOfResearchTargetsTerminatedOncology
Namespace Prefix:	carm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash inflow from the collection of receivables classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:	us-gaap_ProceedsFromCollectionOfOtherReceivables
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount expected to be recognized in earnings for the specified restructuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4.d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4.b.1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 420
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482017/420-10-50-1

+ Details

Name:	us-gaap_RestructuringAndRelatedCostExpectedCost1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The number of positions eliminated during the period as a result of restructuring activities.

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RestructuringPlanAxis=carm_CashPreservationPlan2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details) $ in Millions		1 Months Ended		12 Months Ended
Subsequent Events (Details) $ in Millions	Mar. 31, 2025 USD ($) employee	Feb. 28, 2025 target item	Jan. 31, 2025 USD ($)	Dec. 31, 2024 employee
Employee Severance
Subsequent Event [Line Items]
Reduction in workforce, number of employees \| employee				62
Reduction in workforce (as a percent)				58.00%
Subsequent Event \| Employee Severance \| 2025 Cash Preservation Plan
Subsequent Event [Line Items]
Reduction in workforce, number of employees \| employee	37
Reduction in workforce (as a percent)	84.00%
Expected cost with the reduction in workforce \| $	$ 3.8
Subsequent Event \| Moderna
Subsequent Event [Line Items]
Proceeds from collection of collaboration receivable \| $			$ 2.9
Subsequent Event \| Moderna \| Collaboration and License Agreement
Subsequent Event [Line Items]
Number of oncology research targets, nominated \| item		10
Number of research targets, replacement nominations		4
Number of oncology research targets, ceased development		2
Number of autoimmune research targets, ceased development		2
Number of oncology research targets		12